Renal safety of zoledronic acid with thalidomide in patients with myeloma: A pharmacokinetic and safety sub-study

BMC Clinical Pharmacology

Volumn 8, Issue , 2008, Pages

  Spencer, Andrew ^a   Roberts, Andrew ^b   Kennedy, Nola ^a   Ravera, Christina ^c   Cremers, Serge ^c   Bilic, Sanela ^c   Neeman, Terry ^d   Copeman, Michael ^d   Schran, Horst ^c   Lynch, Kevin ^e  

^a ALFRED HOSPITAL   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Covance Pty Ltd ^*  (Australia)

^e Novartis Pharmaceuticals Australia Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PREDNISOLONE; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KIDNEY FUNCTION; MAINTENANCE THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELOMA; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; KIDNEY; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CREATININE; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; KIDNEY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISOLONE; THALIDOMIDE;

EID: 42649122594     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-8-2     Document Type: Article

References (4)